Dianthus Therapeutics, Inc. /DE/
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
DNTH$88.81-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(137,692) | $(97,905) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 106 | 84 |
| Stock-based compensation expense | 35,221 | 16,815 |
| Accretion of discount on investment securities | (7,753) | (5,308) |
| Amortization of right-of-use operating lease assets | 186 | 247 |
| Loss/(gain) on investment in former related party | 169 | (254) |
| Changes in operating assets and liabilities: | ||
| Receivable from former related party | — | 807 |
| Accounts receivable, net | (530) | (5,000) |
| Prepaid expenses and other current assets | (12,582) | (1,356) |
| Other assets | (2,598) | 565 |
| Accounts payable, accrued expenses and operating lease liabilities | (2,778) | 4,593 |
| Deferred revenue | 80 | 4,635 |
| Net cash used in operating activities | (128,171) | (82,077) |
| Cash flows from investing activities: | ||
| Capital expenditures | (559) | (75) |
| Purchases of investment securities | (1,127,456) | (380,278) |
| Proceeds from sales and maturities of investment securities | 403,651 | 220,317 |
| Net cash used in investing activities | (724,364) | (160,036) |
| Cash flows from financing activities: | ||
| Proceeds from public offering | 677,624 | 272,268 |
| Payment of issuance costs in connection with public offering | (1,544) | (172) |
| Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs | 156,797 | — |
| Proceeds from exercise of stock options | 24,021 | 2,829 |
| Proceeds from issuance of common stock under employee stock purchase plan | 364 | 316 |
| Proceeds from exercise of warrants and pre-funded warrants | 1 | 1 |
| Net cash provided by financing activities | 857,263 | 275,242 |
| Increase in cash, cash equivalents and restricted cash | 4,728 | 33,129 |
| Cash, cash equivalents and restricted cash, beginning of period | 51,254 | 23,022 |
| Cash, cash equivalents and restricted cash, end of period | $55,982 | $56,151 |
| Supplemental Disclosure | ||
| Cash and cash equivalents | $55,686 | $55,984 |
| Restricted cash | 296 | 167 |
| Total cash, cash equivalents and restricted cash | $55,982 | $56,151 |
| Issuance costs in connection with public offering included in accounts payable | $— | $192 |
| Issuance costs in connection with public offering included in accrued expenses | $— | $40 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.